NasdaqGS - Delayed Quote • USD
Halozyme Therapeutics, Inc. (HALO)
At close: April 24 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 5 |
| Avg. Estimate | 0.7 | 0.73 | 3.69 | 4.56 |
| Low Estimate | 0.63 | 0.69 | 3.61 | 4.41 |
| High Estimate | 0.83 | 0.8 | 3.77 | 4.67 |
| Year Ago EPS | 0.47 | 0.74 | 2.77 | 3.69 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 8 |
| Avg. Estimate | 199.78M | 207.53M | 952.44M | 1.08B |
| Low Estimate | 180.71M | 196M | 943.15M | 1.07B |
| High Estimate | 220M | 223M | 966.56M | 1.1B |
| Year Ago Sales | 175.51M | 199.95M | 829.25M | 952.44M |
| Sales Growth (year/est) | 13.80% | 3.80% | 14.90% | 13.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.48 | 0.63 | 0.71 | 0.82 |
| EPS Actual | 0.47 | 0.74 | 0.75 | 0.82 |
| Difference | -0.01 | 0.11 | 0.04 | 0 |
| Surprise % | -2.10% | 17.50% | 5.60% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.7 | 0.73 | 3.69 | 4.56 |
| 7 Days Ago | 0.7 | 0.73 | 3.69 | 4.56 |
| 30 Days Ago | 0.76 | 0.79 | 3.68 | 4.58 |
| 60 Days Ago | 0.77 | 0.81 | 3.55 | 4.43 |
| 90 Days Ago | 0.87 | 0.86 | 3.51 | 4.34 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | -- |
| Up Last 30 Days | -- | 1 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | HALO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 48.90% | -- | -- | 1.50% |
| Next Qtr. | -1.40% | -- | -- | 11.40% |
| Current Year | 33.20% | -- | -- | 5.20% |
| Next Year | 23.60% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 25.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 84.82% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/17/2024 |
| Reiterates | Benchmark: Buy to Buy | 4/16/2024 |
| Initiated | TD Cowen: Outperform | 2/29/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 2/21/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/21/2024 |
| Reiterates | Benchmark: Buy to Buy | 1/19/2024 |
Related Tickers
BPMC Blueprint Medicines Corporation
92.26
-0.03%
UTHR United Therapeutics Corporation
237.00
+1.08%
GMAB Genmab A/S
28.47
-0.32%
INCY Incyte Corporation
51.74
+0.17%
IONS Ionis Pharmaceuticals, Inc.
42.45
+1.46%
LEGN Legend Biotech Corporation
45.17
-4.81%
RARE Ultragenyx Pharmaceutical Inc.
44.28
-1.84%
FOLD Amicus Therapeutics, Inc.
10.54
-1.59%
PTCT PTC Therapeutics, Inc.
25.21
-0.79%
RPRX Royalty Pharma plc
27.98
+0.58%